Evaluation of the effect of pentoxifylline on the prevention of erythrocyte lysis in cardiac surgery patients
Phase 3
- Conditions
- All patients undergo open heart surgery.
- Registration Number
- IRCT20210420051018N1
- Lead Sponsor
- Semnan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Patients undergoing open heart surgery
Absence of blood vessel disease
Patients who do not have hemoglobinopathy or a disorder that causes red blood cell lysis
Patients who do not have a contraindication to pentoxifylline.
Exclusion Criteria
Patients with renal and hepatic insufficiency
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Determination of the effect of pentoxifylline on erythrocyte flexibility in patients undergoing cardiopulmonary bypass. Timepoint: 400 mg pentoxifylline tablets every 8 hours for three days before heart surgery. Method of measurement: check list.;Determining the effect of pentoxifylline on peripheral blood smear changes after surgery. Timepoint: Before surgery and 24 hours after surgery. Method of measurement: Laboratory tests.;Determining the effect of pentoxifylline on hemoglobinuria after surgery. Timepoint: Before surgery and 24 hours after surgery. Method of measurement: Laboratory tests.;Determining the effect of pentoxifylline on serum bilirubin after surgery. Timepoint: Before surgery and 24 hours after surgery. Method of measurement: Laboratory tests.;Determining the effect of pentoxifylline on the percentage of reticulocytes after surgery. Timepoint: Before surgery and 24 hours and 48 hours after surgery. Method of measurement: Laboratory tests.
- Secondary Outcome Measures
Name Time Method